Faster-acting insulin aspart improves postprandial glycaemia versus insulin aspart in patients with type 1 diabetes mellitus

被引：0
|
作者：
Heise, T. [1 ]
Haahr, H. [2 ]
Jensen, L. [2 ]
Erichsen, L. [2 ]
Hompesch, M. [3 ]
机构：
[1] Profil, Neuss, Germany
[2] Novo Nordisk AS, Soborg, Denmark
[3] Profil Inst Clin Res Inc, Chula Vista, CA USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
120
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [1] FASTER-ACTING INSULIN ASPART IMPROVES POSTPRANDIAL GLYCAEMIA VERSUS INSULIN ASPART IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
    Heise, T.
    Haahr, H.
    Jensen, L.
    Erichsen, L.
    Hompesch, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A5 - A6
  • [2] Faster-Acting Insulin Aspart Improves Postprandial Glycemia vs. Insulin Aspart in Patients with Type 1 Diabetes Mellitus (T1DM)
    Heise, Tim
    Haahr, Hanne L.
    Jensen, Lene
    Erichsen, Lars
    Hompesch, Marcus
    DIABETES, 2014, 63 : A34 - A34
  • [3] Pharmacological properties of Faster-acting Insulin Aspart (Faster-acting Insulin aspart)
    Heise, Tim
    Biester, Torben
    DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (05) : 386 - 396
  • [4] IMPROVED POSTPRANDIAL GLYCAEMIC CONTROL WITH FASTER-ACTING INSULIN ASPART VS INSULIN ASPART IN SUBJECTS WITH TYPE 1 DIABETES USING CSII IN PUMPS
    Bode, B. W.
    Hyveled, L.
    Tamer, S. C.
    Demissie, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A40 - A40
  • [5] A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
    Heise, Tim
    Hoevelmann, Ulrike
    Zijlstra, Eric
    Stender-Petersen, Kirstine
    Jacobsen, Jacob Bonde
    Haahr, Hanne
    DRUGS & AGING, 2017, 34 (01) : 29 - 38
  • [6] A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Ulrike Hövelmann
    Eric Zijlstra
    Kirstine Stender-Petersen
    Jacob Bonde Jacobsen
    Hanne Haahr
    Drugs & Aging, 2017, 34 : 29 - 38
  • [7] Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus
    Fath, Maryam
    Danne, Thomas
    Biester, Torben
    Erichsen, Lars
    Kordonouri, Olga
    Haahr, Hanne
    PEDIATRIC DIABETES, 2017, 18 (08) : 903 - 910
  • [8] PROJECTED LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES MELLITUS TREATED WITH FASTER-ACTING INSULIN ASPART VERSUS CONVENTIONAL INSULIN ASPART IN THE UK SETTING
    Russell-Jones, D.
    Buchs, S.
    Jensen, M. M.
    Hunt, B.
    Valentine, W. J.
    Heller, S.
    VALUE IN HEALTH, 2016, 19 (07) : A671 - A671
  • [9] Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
    Heise, Tim
    Stender-Petersen, Kirstine
    Hoevelmann, Ulrike
    Jacobsen, Jacob Bonde
    Nosek, Leszek
    Zijlstra, Eric
    Haahr, Hanne
    CLINICAL PHARMACOKINETICS, 2017, 56 (06) : 649 - 660
  • [10] Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Kirstine Stender-Petersen
    Ulrike Hövelmann
    Jacob Bonde Jacobsen
    Leszek Nosek
    Eric Zijlstra
    Hanne Haahr
    Clinical Pharmacokinetics, 2017, 56 : 649 - 660
12345